WHO ICTRP trial
JCOG1213: Randomized phase III study of etoposide plus cisplatin combination…
JPRN-jRCTs031180005 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-jRCTs031180005 |
|---|---|
| Public title | JCOG1213: Randomized phase III study of etoposide plus cisplatin combination therapy versus irinotecan plus cisplatin combination therapy in advanced neuroendocrine carcinoma of the digestive system. |
| Scientific title | JCOG1213: Randomized phase III study of etoposide plus cisplatin combination therapy versus irinotecan plus cisplatin combination therapy in advanced neuroendocrine carcinoma of the digestive system. - TOPIC-NEC |
| Primary sponsor | OKUSAKA Takuji |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 3 |
| Conditions | advanced neuroendocrine carcinoma of the digestive system |
| Interventions | A: Chemotherapy with etoposide (100 mg/m2/day, day 1,2,3) and cisplatin (80 mg/m2/day, day 1) repeated every 3 weeks B: Chemotherapy with irinotecan (60 mg/m2/day, day 1,8,15) and cisplatin (60 mg/m2/day, day 1) repeated every 4 weeks. |
| Registration date | Jan 23, 2019 |
| Target size | 170 |
| Secondary IDs | UMIN000014795 |
| Registry page | jrct.niph.go.jp |
At a glance
- Yes Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: